Skip to main content

2 Result(s)

within Tanya T. Kwan Remove this filter

and

  1. Article

    Open Access

    Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

    ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post...

    Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker… in Nature Communications (2021)

    Download PDF (2075 KB) View Article

  2. No Access

    Chapter

    Quantitative Analysis of Circulating Tumor Cells Using RNA-Based Digital Scoring

    Circulating tumor cells (CTCs) provide valuable information about the molecular evolution of cancers, as they may initially respond and ultimately progress on therapy. As intact tumor cells isolated from the b...

    Mark Kalinich, Tanya T. Kwan, Mehmet Toner, Daniel A. Haber… in Tumor Liquid Biopsies (2020)